The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis

被引:2
作者
Atia, Ohad [1 ]
Gupta, Arun [2 ]
Travis, Simon [3 ]
Turner, Dan [1 ]
Koslowsky, Benjamin [4 ,5 ]
机构
[1] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Juliet Keidan Inst Pediat Gastroenterol Hepatol &, Jerusalem, Israel
[2] John Radcliffe Hosp, Oxford, England
[3] Oxford Univ Hosp NHS Fdn Trust, John Radcliffe Hosp, NIHR Oxford Biomed Res Ctr, Translat Gastroenterol Unit, Oxford, England
[4] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[5] Shaare Zedek Med Ctr, Digest Dis Inst, Jerusalem, Israel
关键词
PUCAI; acute sever colitis; corticosteroids failure; FECAL CALPROTECTIN; CLINICAL-COURSE; OUTCOMES; ATTACKS;
D O I
10.1080/00365521.2021.1947368
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background One-third of patients with acute severe ulcerative colitis (ASC) fail to respond to intravenous corticosteroids (IVCS) and require second-line therapy or colectomy. We aimed to explore the performance of the Pediatric Ulcerative Colitis Activity Index (PUCAI), for predicting response to IVCS in adults with ASC, and to base a two-step decision-making process for guiding the introduction of second-line therapy. Methods This was a retrospective multicenter cohort study of adult patients with ASC. PUCAI score, Oxford criteria, and Swedish index were determined at baseline, day three and five of hospitalization, and discharge when outcomes were ascertained. Results 153 patients were included (mean age 34.7 +/- 14.6, median disease duration 7.8 years [IQR 0-17.4]), of whom 51 (33%) required second-line therapy, and 23 (15%) eventually underwent colectomy by discharge. At days three and five, the median PUCAI scores were higher in non-responders compared with responders (55 [45-69] vs. 38 [25-55] at day 3, and 55 [36-65] vs. 20 [5-30] at day 5; both p < .001). The negative and positive predictive values (NPV and PPV) of IVCS failure were 76/63% for the Oxford criteria, 83/52% for the Swedish index as determined on day 3, and 73/100% for PUCAI >= 65 points on day five. The corresponding figures for PUCAI >= 45 at day 3 were 83/54%. Conclusion The PUCAI is a highly predictive tool for IVCS failure. PUCAI >= 45 on day 3 has an excellent NPV for IVCS failure indicating preparation for second-line therapy, and PUCAI >= 65 on day 5 has a high PPV to initiate the therapy.
引用
收藏
页码:1049 / 1055
页数:7
相关论文
共 50 条
  • [21] Fecal calprotectin as an alternative to ulcerative colitis endoscopic index of severity to predict the response to corticosteroids of acute severe ulcerative colitis: A prospective observational study
    Xie, Tingbin
    Zhao, Chenyan
    Ding, Chao
    Zhang, Tenghui
    Dai, Xujie
    Lv, Tengfei
    Li, Yi
    Guo, Zhen
    Gong, Jianfeng
    Zhu, Weiming
    [J]. DIGESTIVE AND LIVER DISEASE, 2017, 49 (09) : 984 - 990
  • [22] Albumin change predicts failure in ulcerative colitis treated with adalimumab
    Ishida, Natsuki
    Takahashi, Kenichi
    Asai, Yusuke
    Miyazu, Takahiro
    Tamura, Satoshi
    Tani, Shinya
    Yamade, Mihoko
    Iwaizumi, Moriya
    Hamaya, Yasushi
    Osawa, Satoshi
    Sugimoto, Ken
    [J]. PLOS ONE, 2024, 19 (01):
  • [23] Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis
    Xie, Tingbin
    Zhang, Tenghui
    Ding, Chao
    Dai, Xujie
    Li, Yi
    Guo, Zhen
    Wei, Yao
    Gong, Jianfeng
    Zhu, Weiming
    Li, Jieshou
    [J]. GASTROENTEROLOGY REPORT, 2018, 6 (01): : 38 - 44
  • [24] Acute Severe Ulcerative Colitis in Children: A Systematic Review
    Turner, Dan
    Griffiths, Anne M.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 (01) : 440 - 449
  • [25] Viral Enteric Infections in Acute Severe Ulcerative Colitis
    Ostrowski, Szymon
    Croft, Anthony
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 (08) : 1335 - 1339
  • [26] Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis
    Syal, Gaurav
    Robbins, Lori
    Kashani, Amir
    Bonthala, Nirupama
    Feldman, Edward
    Fleshner, Phillip
    Vasiliauskas, Eric
    McGovern, Dermot
    Ha, Christina
    Targan, Stephan
    Melmed, Gil Y.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (01) : 199 - 205
  • [27] Predicting the Course of Disease in Hospitalized Patients With Acute Severe Ulcerative Colitis
    Bernardo, Sonia
    Fernandes, Samuel Raimundo
    Goncalves, Ana Rita
    Valente, Ana
    Baldaia, Cilenia
    Santos, Paula Moura
    Correia, Luis Araujo
    [J]. INFLAMMATORY BOWEL DISEASES, 2019, 25 (03) : 541 - 546
  • [28] Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine
    Laharie, David
    Bourreille, Arnaud
    Branche, Julien
    Allez, Matthieu
    Bouhnik, Yoram
    Filippi, Jerome
    Zerbib, Frank
    Savoye, Guillaume
    Vuitton, Lucine
    Moreau, Jacques
    Amiot, Aurelien
    Beaugerie, Laurent
    Ricart, Elena
    Dewit, Olivier
    Lopez-Sanroman, Antonio
    Fumery, Mathurin
    Carbonnel, Franck
    Buisson, Anthony
    Coffin, Benoit
    Roblin, Xavier
    van Assche, Gert
    Esteve, Maria
    Farkkila, Martti
    Gisbert, Javier P.
    Marteau, Philippe
    Nahon, Stephane
    de Vos, Martine
    Peyrin-Biroulet, Laurent
    Mary, Jean-Yves
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (06) : 1180 - +
  • [29] Review article: the practical management of acute severe ulcerative colitis
    Seah, D.
    De Cruz, P.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (04) : 482 - 513
  • [30] Cyclosporine Therapy as a Rescue Treatment in Steroid Refractory Acute Severe Ulcerative Colitis: A Real Life Data From a Tertiary Center
    Evirgen, Sami
    Iliaz, Raim
    Akyuz, Filiz
    Cavus, Bilger
    Gokturk, Suut
    Ormeci, Asli
    Soyer, Ozlem Mutluay
    Baran, Bulent
    Pinarbasi, Binnur
    Karaca, Cetin
    Demir, Kadir
    Besisik, Fatih
    Kaymakoglu, Sabahattin
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2022, 33 (06) : 463 - 469